P300 Health related quality of life results through week 22 from the CERTIFI study, a multicenter, randomized, double-blind, placebo-controlled Phase2b study of ustekinumab in patients with moderately to severely active Crohn's diseaseB. Feagan, B E Sands, Ling Gao et al.|Journal of Crohn s and Colitis|2012Cited by 9